Amendments to the Claims:

1. (Original) A method of evaluating a cell's metastatic propensity, said method comprising:

assaying said cell for the presence of at least one target protein associated with cellular locomotion to obtain a result; and

using said result to evaluate said cell's metastatic propensity.

2. (Original) The method according to Claim 1, wherein said at least one target protein is a nucleus-associated ribbon-like structure protein.

3. (Original) The method according to Claim 1, wherein said nucleus-associated ribbon-like structure protein is chosen from:

Leukotriene B4 12-hydroxydehydrogenase (LTB4DH);

Pregnancy-induced growth inhibitor (OKL38);

Hs.516830 (C20orf139);

cyp4 proteins; and

Tripartite-containing motif 29 (TRIM29).

4. (Original) The method according to Claim 1, wherein said at least one target protein is a leading edge cellular locomotion protein.

5. (Original) The method according to Claim 4, wherein said leading edge cellular locomotion protein is Neurotrophic tyrosine kinase receptor type 2 (NTRK2/TrkB).

6. (Original) The method according to Claim 1, wherein said assaying comprises assaying said cell for the presence of at least two different target proteins in said cell.

7. (Original) The method according to Claim 1, wherein said assay comprises assaying said cell for the presence of a nucleus-associated ribbon-like structure.

8. (Original) The method according to Claim 7, wherein said nucleus-associated ribbon-like structure comprises:

Leukotriene B4 12-hydroxydehydrogenase (LTB4DH);

Pregnancy-induced growth inhibitor (OKL38);

Hs.516830 (C20orf139);

cyp4 proteins; and

Tripartite-containing motif 29 (TRIM29).

9. (Original) The method according to Claim 1, wherein said cell is a neoplastic cell.

10. (Original) The method according to Claim 9, wherein said neoplastic cell is a tumor cell.

11. (Original) The method according to Claim 10, wherein said tumor cell is from a tumor harvested from a subject suffering from a neoplastic disease.

12. (Original) The method according to Claim 11, wherein said neoplastic disease is a lung cancer.

13. (Original) The method according to Claim 12, wherein said lung cancer is adenocarcinoma.

14. (Original) A method of making a prognosis for a subject suffering from a neoplastic disease, said method comprising:

assaying a cell obtained from said subject for the presence of at least one target protein associated with cellular locomotion to obtain a result; and

using said result to make a prognosis for said subject.

15. (Original) The method according to Claim 14, wherein said at least one target protein is a nucleus-associated ribbon-like structure protein.

16. (Original) The method according to Claim 15, wherein said nucleus-associated ribbon-like structure protein is chosen from:

Leukotriene B4 12-hydroxydehydrogenase (LTB4DH);

Pregnancy-induced growth inhibitor (OKL38);

Hs.516830 (C20orf139);

cyp4 proteins; and

Tripartite-containing motif 29 (TRIM29).

17-54. (Cancelled)

55. (Original) A kit for use in evaluating a cell's metastatic propensity, said kit comprising:

a reagent for assaying a cell for the presence of at least one target protein associated with cellular locomotion .

56. (Original) The kit according to Claim 55, wherein said at least one target protein is a nucleus-associated ribbon-like structure protein.

57. (Original) The kit according to Claim 56 wherein said nucleus-associated ribbon-like structure protein is chosen from:

Leukotriene B4 12-hydroxydehydrogenase (LTB4DH);

Pregnancy-induced growth inhibitor (OKL38);

Hs.516830 (C20orf139);

cyp4 proteins; and

Tripartite-containing motif 29 (TRIM29).

58-80. (Cancelled)